Arcellx (ACLX)
(Delayed Data from NSDQ)
$86.20 USD
+3.30 (3.98%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $86.13 -0.07 (-0.08%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ACLX 86.20 +3.30(3.98%)
Will ACLX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ACLX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ACLX
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
ACLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Gilead Sciences (GILD) Q2 Earnings and Revenues Beat Estimates
Alkermes (ALKS) Lags Q2 Earnings Estimates
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
Other News for ACLX
Cormorant Asset Management's Strategic Acquisition of Reneo Pharmaceuticals Shares
Perceptive Advisors LLC Acquires New Stake in Reneo Pharmaceuticals Inc
Arcellx initiated with bullish view at Redburn Atlantic, here's why
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc
Buy Rating for Arcellx Inc. on Strong Efficacy and Safety Profile of Anito-cel in RRMM